Publications
Safi S, Krzykalla J, Hoffmann H, Benner A, Bischoff H, Eichhorn M, Kriegsmann M, Poschke I, Stögbauer F, Umansky L, Mogler C, Weichert W, Winter H, Beckhove P, Muley T.
Low tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.
Pulmonology. 2024 Apr 12
https://pubmed.ncbi.nlm.nih.gov/38614857/
Tan CL, Lindner K, Boschert T, Meng Z, Rodriguez Ehrenfried A, De Roia A, Haltenhof G, Faenza A, Imperatore F, Bunse L, Lindner JM, Harbottle RP, Ratliff M, Offringa R, Poschke I, Platten M, Green EW.
Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy.
Nat Biotechnol. 2024 Mar 7
https://pubmed.ncbi.nlm.nih.gov/38454173/
Boschert T, Kromer K, Lerner T, Lindner K, Haltenhof G, Tan CL, Jähne K, Poschke I, Bunse L, Eisele P, Grassl N, Mildenberger I, Sahm K, Platten M, Lindner JM, Green EW.
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
Sci Adv, 2924 Feb 2
https://pubmed.ncbi.nlm.nih.gov/38306431/
Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F.
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Front Immunol. 2024 Jan 4
https://pubmed.ncbi.nlm.nih.gov/38239352/
Grassl N, Sahm K, Süße H, Poschke I, Bunse L, Bunse T, Boschert T, Mildenberger I, Rupp AK, Ewinger MP, Lanz LM, Denk M, Tabatabai G, Ronellenfitsch MW, Herrlinger U, Glas M, Krex D, Vajkoczy P, Wick A, Harting I, Sahm F, von Deimling A, Bendszus M, Wick W, Platten M.
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas.
Neurol Res Pract. 2023 Oct 19
https://pubmed.ncbi.nlm.nih.gov/37853454/
Grassl N, Poschke I, Lindner K, Bunse L, Mildenberger I, Boschert T, Jähne K, Green EW, Hülsmeyer I, Jünger S, Kessler T, Suwala AK, Eisele P, Breckwoldt MO, Vajkoczy P, Grauer OM, Herrlinger U, Tonn JC, Denk M, Sahm F, Bendszus M, von Deimling A, Winkler F, Wick W, Platten M, Sahm K.
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Nat Med. 2023 Oct;29
https://pubmed.ncbi.nlm.nih.gov/37735561/
Lu KH, Michel J, Kilian M, Aslan K, Qi H, Kehl N, Jung S, Sanghvi K, Lindner K, Zhang XW, Green EW, Poschke I, Ratliff M, Bunse T, Sahm F, von Deimling A, Wick W, Platten M, Bunse L.
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells.
Neurooncol Adv. 2022 Aug 31
https://pubmed.ncbi.nlm.nih.gov/36196364/
Liebers N, Speer C, Benning L, Bruch PM, Krämer I, Meissner J, Schnitzler P, Kräusslich HG, Dreger P, Müller-Tidow C, Poschke I, Dietrich S.
Humoral and cellular responses after COVID-19 vaccination in anti-CD20 treated lymphoma patients.
Blood. 2021 published online 10/2021
https://pubmed.ncbi.nlm.nih.gov/34669919/
Platten M, Bunse L, Wick A, Bunse T, Le Cornet L, Harting I, Sahm F, Sanghvi K, Tan CL, Poschke I, Green E, Justesen S, Behrens GA, Breckwoldt MO, Freitag A, Rother LM, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Stevanovic S, Tabatabai G, Steinbach JP, Bendszus M, von Deimling A, Schmitt M, Wick W.
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Nature. 2021 Apr;592(7854):463-468.
https://pubmed.ncbi.nlm.nih.gov/33762734/
Bunse L, Rupp AK, Poschke I, Bunse T, Lindner K, Wick A, Blobner J, Misch M, Tabatabai G, Glas M, Schnell O, Gempt J, Denk M, Reifenberger G, Bendszus M, Wuchter P, Steinbach JP, Wick W, Platten M.
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas.
Neurol Res Pract. 2022 May 23 ; https://pubmed.ncbi.nlm.nih.gov/35599302/
van Tilburg CM, Witt R, Heiss M, Pajtler KW, Plass C, Poschke I, Platten M, Harting I, Sedlaczek O, Freitag A, Meyrath D, Taylor L, Balasubramanian GP, Jäger N, Pfaff E, Jones BC, Milde T, Pfister SM, Jones DTW, Kopp-Schneider A, Witt O.
INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
BMC Cancer. 2020 Jun 5;20(1):523.
https://pubmed.ncbi.nlm.nih.gov/32503469/
Poschke IC, Hassel JC, Rodriguez-Ehrenfried A, Lindner KAM, Heras-Murillo I, Appel LM, Lehmann J, Lövgren T, Wickström SL, Lauenstein C, Roth J, König AK, Haanen JBAG, van den Berg J, Kiessling R, Bergmann F, Flossdorf M, Strobel O, Offringa R.
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones.
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301. Epub 2020 Apr 17.
https://pubmed.ncbi.nlm.nih.gov/32303540/
Clin Cancer Res. 2019 Mar 15;25(6):1851-1866.
https://www.ncbi.nlm.nih.gov/pubmed/30530705
Oncoimmunology. 2019 Oct 23;8(12):e1671762.
https://www.ncbi.nlm.nih.gov/pubmed/31741774
Cancer Immunol Res. 2019 Dec;7(12):1998-2012
https://www.ncbi.nlm.nih.gov/pubmed/31672785
Methods Enzymol. 2019;629:401-417.
https://www.ncbi.nlm.nih.gov/pubmed/31727251
Methods Enzymol. 2019;629:419-441.
https://www.ncbi.nlm.nih.gov/pubmed/31727252
Front Immunol. 2019 Jun 11;10:1302
https://www.ncbi.nlm.nih.gov/pubmed/31244848
Nature. 2019 Jan;565(7738):240-245.Erratum in: Nature. 2019 Feb;566(7745):E13.
https://www.ncbi.nlm.nih.gov/pubmed/30568303
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Nat Med. 2018 Aug;24(8):1192-1203
Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D, Karapanagiotou-Schenkel I, Harting I, Sahm F, Schmitt A, Steinbach J, Weyerbrock A, Hense J, Misch M, Krex D, Stevanović S, Tabatabai G, von Deimling A, Schmitt M, Wick W (2018).
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
Oral presentation at the Annual ASCO Conference 2018
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.2001
Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Babera JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling A, Schuhmann M, Herold-Mende C, Korshunov A, Brummer T, Pfister SM, Jones DTW, Witt O, Milde T.
The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma.
Clin Cancer Res. 2018 Dec 7.
Wabnitz GH, Kirchgessner H, Jahraus B, Umansky L, Shenolikar S, Samstag Y.
Protein Phosphatase 1αand Cofilin Regulate Nuclear Translocation of NF-κB and Promote Expression of the Anti-Inflammatory Cytokine Interleukin-10 by T Cells.
Mol Cell Biol. 2018 Oct 29;38(22).
Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V.
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787
Platten M, Bunse L, Riehl D, Bunse T, Ochs K, Wick W.
Vaccine Strategies in Gliomas.
Curr Treat Options Neurol. 2018 Mar 28;20(5):11.
Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D.
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. Eur J Cancer. 2018 Feb;90:122-129
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P.
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Oncoimmunology. 2018 Jan 16;7(4)
https://www.ncbi.nlm.nih.gov/pubmed/29632710
Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C.
Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens.
Acta Neuropathol. 2017 Aug;134(2):297-316
Rathinasamy A, Domschke C, Ge Y, Böhm HH, Dettling S, Jansen D, Lasitschka F, Umansky L, Gräler MH, Hartmann J, Herold-Mende C, Schuetz F, Beckhove P.
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1.
Cancer Immunol Immunother. 2017 May;66(5):593-603.
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M. K27M-mutant histone-3 as a novel target for glioma immunotherapy.
Oncoimmunology. 2017 May 12;6(7)
Wiskemann J., Hummler S., Diepold C., Keil M., Abel U., Steindorf K., Beckhove P., Ulrich C.M., Steins M. and Thomas M.;
POSITIVE study: physical exercise program in non-operable lung cancer patients undergoing palliative treatment.
BMC Cancer. 2016 Jul 16:499 DOI: 10.1186/s12885-016-2561-1
Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz, T., Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V.
Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
Clin. Cancer Res., 2015, DOI:10.158/1078-0432.CCR-15-0676.
Schneider T, Sevko A, Heussel CP, Umansky L, Beckhove P, Dienemann H, Safi S, Utikal J, Hoffmann H, Umansky V.
Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small cell lung cancer.
Clin Exp Immunol. 2015, 180:467-474.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P.
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Oncoimmunology. 2015 Mar 16;4(4):1001217. eCollection 2015 Apr.
Domschke C., Ge Y., Bernahrd I., Schott S., Keim S., Juenger S., Bucur M., Mayer L., Blumenstein M., Rom J., Heil J., Sohn C., Schneeweiss A., Beckhove P., Schetz F.,
Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized brest cancer: follow-up analysis of clinical pilot trial.
Cancer Immunol Immunother. 2013 Jun;62(6):1053-60. Doi: 10.1007/s00262-013-1414-x Epub 2013 Apr 18.